BD trading is surging; innovative drug stocks are entering a period of intensive data-driven catalysts; and the Bosera Hang Seng China Innovative Drugs ETF has gained more than 14% cumulatively over the past week.

Ask AI · What are the core driving factors behind the recent surge in Hong Kong-listed innovative drug ETFs?

Since 2026, China’s innovative drug BD transaction volume has exceeded expectations, further enhancing the industry’s global competitiveness; the domestic market has rapidly expanded, and according to the 2025 annual report, leading innovative drug companies have seen rapid revenue growth driven by new products, with biopharmaceuticals gradually reaching profitability inflection points; several international academic conferences are upcoming, with many innovative drug pipelines entering intensive data catalysis periods.

CICC Securities pointed out that in March 2026, the innovative drug sector rebounded strongly, mainly benefiting from the normalization of BD transactions, continuous optimization of commercialized product volume and report structure, coupled with increased expectations for key data releases at AACR 2026 and ASCO 2026, further strengthening the logic of “going global from follow to leading”; the adjustment and technical support of the Hong Kong biotech and pharmaceutical index are sufficient, and amid a correction in AI tech stocks, innovative drugs have become a “safe-haven direction” among growth stocks with margin of safety.

As of 10:22 on April 3, 2026, the Hong Kong-listed innovative drug ETF Boshi (520690) declined 0.34%, with the latest price at 0.87 yuan. Looking at a longer timeframe, as of April 2, 2026, the Hong Kong-listed innovative drug ETF Boshi has increased by 14.30% over the past week.

In terms of liquidity, the Hong Kong-listed innovative drug ETF Boshi had an intraday turnover of 11.84%, with a trading volume of 63.04 million yuan, indicating active market trading. Over the longer term, as of April 2, the ETF’s average daily trading volume over the past week was 329M yuan.

The Hong Kong-listed innovative drug ETF Boshi closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and manufacturing that are accessible via the Hong Kong Stock Connect.

Data shows that as of April 2, 2026, the top ten holdings of the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) are Kangfang Biotech, Innovent Biologics, CSPC Pharmaceutical Group, BeiGene, China Biological Products, Hansoh Pharmaceutical, Sihuan Pharmaceutical, Kelun-Biotech, Yimeng Biological-B, and Rongchang Biotech, with the top ten holdings accounting for 69.65% of the total.

Related products: Hong Kong-listed innovative drug ETF Boshi (520690); Hang Seng Healthcare ETF Boshi (513060), off-market connection ( Boshi Hang Seng Healthcare & Biotech ETF Launch-Style Connection (QDII)A: 014424; Boshi Hang Seng Healthcare & Biotech ETF Launch-Style Connection (QDII)C: 014425).

(Note: individual stocks mentioned are for illustration only and do not constitute actual investment advice. Funds carry risks; investments should be cautious.) The risk level of these products is: medium-high (this is the manager’s rating; specific sales are subject to the ratings of each distribution institution). Risk reminder: Funds differ from fixed-income financial instruments like bank savings and bonds, which have predictable returns. Different types of funds have different risk-return profiles; investors may share in the gains from fund investments or bear losses. Past performance does not indicate future results. Investors should understand the risk-return profile of the fund, consider their own investment objectives, time horizon, experience, and risk tolerance, and make cautious decisions and bear risks independently. Do not rely on sales behaviors or promotional materials that do not comply with legal and regulatory requirements.